PharmaShots: Roy Maute on Macrophage Checkpoint Inhibition: Pheast’s Vision for Advancing PHST001 in Solid Tumors

In this PharmaShots interview, Pheast Therapeutics’ CEO Roy Maute outlines the scientific and strategic rationale for targeting macrophage checkpoints as a complementary immuno-oncology approach, focused on blocking “don’t eat me” signals that enable tumor immune evasion. He discusses how Pheast’s lead program, PHST001, targets the CD24 “shield” on cancer cells to improve the anti-cancer response. The conversation reinforces Pheast’s broader vision to establish macrophage checkpoint inhibitors as a differentiated, combination-ready modality that can expand the application and effectiveness of cancer immunotherapy.

Read the full article here.